ABSTRACT

Tamoxifen is a member of the selective estrogen modulator (SERM) family. SERMs exert selective agonist or antagonist effects on various estrogen target tissues. Tamoxifen is used as an adjuvant treatment in early and advanced breast cancer patients. Aphthous oral ulcers are painful lesions of the oral mucosa and are common in the general population. Usually the etiology is unknown. Herein we present a patient with breast cancer who had recurrent oral aphthous lesions that occurred following tamoxifen treatment.